We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

We recently published a list of the 15 Best and Cheap Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands ...

The success of products like Breyanzi in certain patient populations and the potential of the GPRC5D CAR T therapy in multiple myeloma underscore BMY’s commitment to innovation. However ...

The stent hadn’t helped after all; the impacted kidney had, in fact, been irreversibly damaged and was now functioning at a ...

The success of products like Breyanzi in certain patient populations and the potential of the GPRC5D CAR T therapy in multiple myeloma underscore BMY’s commitment to innovation. However, the company ...

Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...

CAR-T pipeline advances, with blood cancers at the forefront of development, driving new treatment innovations.

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Breyanzi’s approval is based on the TRANSCEND NHL 001 trial involving 268 patients, which showed that 54% of those taking Breyanzi had minimal or no detectable lymphoma remaining after treatment ...

In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of ...

A third CD19-targeted CAR-T, Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel), is on the market for other blood cancers, but not ALL. Aucatzyl will now have to carve out market share ...

Final guidance published today recommends lisocabtagene maraleucel (also known as liso-cel or Breyanzi, made by Bristol Myers ...